Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Dear TrialNet Family,
We are thrilled to announce that the Teplizumab Prevention Study is the first to show clinical type 1 diabetes (T1D) can be delayed for a median of two years in children and adults at high risk. The results were announced on June 9, 2019 at the American Diabetes Association’s 79th Annual Scientific Sessions and published in the New England Journal of Medicine.
As we announce these breakthrough findings, We’d like to take a moment to thank everyone who made the Teplizumab (Anti-CD3) Prevention Study possible:
This is an incredible advancement that gets us one step closer to our ultimate goal: a future without T1D.
Kevan Herold, M.D.
TrialNet Teplizumab Study Chair
Professor of Immunobiology and Medicine, Yale University
Carla Greenbaum, M.D.
Diabetes Program Director, Benaroya Research Institute at Virginia Mason
Previous clinical studies have shown the benefit of teplizumab in prolonging insulin production in people recently diagnosed with T1D.
This is the first study to test teplizumab’s ability to delay or prevent disease progression in those at high risk for developing T1D.
All study participants had two or more T1D autoantibodies and abnormal blood sugar levels (Stage 2 T1D) prior to enrollment, as identified by TrialNet Pathway to Prevention risk screening. Individuals in Stage 2 have a lifetime risk of clinical diagnosis (Stage 3 T1D) nearing 100%.
Researchers enrolled 76 people between the ages of 8 and 49; 55 were under age 18. All participants had at least one relative with type 1 diabetes.
Participants were randomly assigned to either the treatment group, which received a 14-day course of teplizumab, or the control group, which received a placebo. All participants regularly underwent oral glucose tolerance tests either until the study was completed or until they developed clinical type 1 diabetes.
In addition, TrialNet is continually planning and launching new studies. As always, we encourage family members of people with T1D to get screened through the Pathway to Prevention Study.
I am a current TrialNet Participant
I am a member of the Media
I am a Health Care Provider
I am a Researcher who is interested in using samples to conduct additional research